These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 25953263)
1. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263 [TBL] [Abstract][Full Text] [Related]
2. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes. Farhadi E; Zaker F; Safa M; Rezvani MR Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565 [TBL] [Abstract][Full Text] [Related]
3. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594 [TBL] [Abstract][Full Text] [Related]
4. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Jiang X; Cheng Y; Hu C; Zhang A; Ren Y; Xu X Leuk Lymphoma; 2019 Jul; 60(7):1709-1720. PubMed ID: 30516071 [TBL] [Abstract][Full Text] [Related]
6. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176 [TBL] [Abstract][Full Text] [Related]
7. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453 [TBL] [Abstract][Full Text] [Related]
8. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039 [TBL] [Abstract][Full Text] [Related]
9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells. Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340 [TBL] [Abstract][Full Text] [Related]
12. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. Bhutra S; Lenkala D; LaCroix B; Ye M; Huang RS PLoS One; 2014; 9(12):e115003. PubMed ID: 25506832 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of Deng Y; Li X; Feng J; Zhang X Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564 [TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934 [TBL] [Abstract][Full Text] [Related]
15. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793 [TBL] [Abstract][Full Text] [Related]
16. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib. Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375 [TBL] [Abstract][Full Text] [Related]
18. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Kosova B; Tezcanli B; Ekiz HA; Cakir Z; Selvi N; Dalmizrak A; Kartal M; Gunduz U; Baran Y Leuk Lymphoma; 2010 Oct; 51(10):1895-901. PubMed ID: 20849385 [TBL] [Abstract][Full Text] [Related]
19. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649 [TBL] [Abstract][Full Text] [Related]
20. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells. Wang XY; Sun GB; Wang YJ; Yan F Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]